Fairmount Funds Management, Director, 10% Stockholder: Oruka Therapeutics ORKA Planned sale · Filed 07/01

Trade details

Type: Planned sale notice
Stock: Oruka Therapeutics ORKA
Person: Fairmount Funds ManagementDirector, 10% Stockholder
Planned sale date: 26/07/01
Filed: 26/07/01

5.9% of shares outstanding to be sold

Oruka Therapeutics trades, last 26 weeks

What else happened in Oruka Therapeutics around then

Filed or reported within 30 days of the trade day · 06/01~07/31

Fairmount Funds Management's recent trades

Fairmount Funds ManagementDirector
Planned saleSpyre Therapeutics
Planned sale
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
SellSpyre Therapeutics
Sell
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
BuyViridian Therapeutics, Inc.\DE
Buy
Viridian Therapeutics, Inc.\DE
VRDN
$20M
1,176,470 sh
$20M
Filed 05/13
Traded 05/11
Fairmount Funds ManagementDirector
BuyZenas BioPharma
Buy
Zenas BioPharma
ZBIO
$3M
150,000 sh
$3M
Filed 04/01
Traded 03/31
Fairmount Funds ManagementDirector
Planned saleCogent Biosciences
Planned sale
Cogent Biosciences
COGT
$242.6M
7,000,000 sh
$242.6M
Filed 03/31
Traded 03/31

Fairmount Funds Management, 10% Owner — plans to sell 3,553,410 sh of Oruka Therapeutics ORKA · $300M · around 07/01 | Whalegun